Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Roeland Lameris"'
Autor:
Tanja D de Gruijl, Roeland Lameris, Jamie Rossjohn, Myrthe Veth, David Lutje Hulsik, Adam Shahine, Bart Westerman, Dale I Godfrey, Patricia Brouwer, Hans J van der Vliet
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 12 (2023)
Background CD1d is a monomorphic major histocompatibility complex class I-like molecule that presents lipid antigens to distinct T-cell subsets and can be expressed by various malignancies. Antibody-mediated targeting of CD1d on multiple myeloma cell
Externí odkaz:
https://doaj.org/article/44eecee2a3e44705a7cd0649a4af661d
Autor:
Henk Verheul, Tanja de Gruijl, Elisa Toffoli, Abdolkarim Sheikhi, Roeland Lameris, Lisa King, Jurriaan Tuynman, Jan Spanholtz, Hans Van der Vliet
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)
Externí odkaz:
https://doaj.org/article/71c0306515094122a8cf926b1c58d71f
Autor:
Elisa C. Toffoli, Abdolkarim Sheikhi, Roeland Lameris, Lisa A. King, Amanda van Vliet, Bruce Walcheck, Henk M. W. Verheul, Jan Spanholtz, Jurriaan Tuynman, Tanja D. de Gruijl, Hans J. van der Vliet
Publikováno v:
Cancers, Vol 13, Iss 21, p 5446 (2021)
The ability to kill tumor cells while maintaining an acceptable safety profile makes Natural Killer (NK) cells promising assets for cancer therapy. Strategies to enhance the preferential accumulation and activation of NK cells in the tumor microenvir
Externí odkaz:
https://doaj.org/article/1660bc09e044423aabcf4544536051f8
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Externí odkaz:
https://doaj.org/article/9e4052d1ac234049a24a1a5b475129b8
Autor:
Renée Poels, Esther Drent, Roeland Lameris, Afroditi Katsarou, Maria Themeli, Hans J. van der Vliet, Tanja D. de Gruijl, Niels W. C. J. van de Donk, Tuna Mutis
Publikováno v:
International Journal of Molecular Sciences, Vol 22, Iss 3, p 1096 (2021)
Due to the CD1d restricted recognition of altered glycolipids, Vα24-invariant natural killer T (iNKT) cells are excellent tools for cancer immunotherapy with a significantly reduced risk for graft-versus-host disease when applied as off-the shelf-th
Externí odkaz:
https://doaj.org/article/1a86429bc28f4cbc904fa745f2ad0fdb
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
CD1d-restricted invariant natural killer T (iNKT) cells are considered an attractive target for cancer immunotherapy. Upon their activation by glycolipid antigen and/or cytokines, iNKT cells can induce direct lysis of tumor cells but can also induce
Externí odkaz:
https://doaj.org/article/fac83e0d0dbd4bccb870c7aec3c2b836
Autor:
Renée C. G. de Bruin, John P. Veluchamy, Sinéad M. Lougheed, Famke L. Schneiders, Silvia Lopez-Lastra, Roeland Lameris, Anita G. Stam, Zsolt Sebestyen, Jürgen Kuball, Carla F. M. Molthoff, Erik Hooijberg, Rob C. Roovers, James P. Di Santo, Paul M. P. van Bergen en Henegouwen, Henk M. W. Verheul, Tanja D. de Gruijl, Hans J. van der Vliet
Publikováno v:
OncoImmunology, Vol 7, Iss 1 (2018)
Though Vγ9Vδ2-T cells constitute only a small fraction of the total T cell population in human peripheral blood, they play a vital role in tumor defense and are therefore of major interest to explore for cancer immunotherapy. Vγ9Vδ2-T cell-based
Externí odkaz:
https://doaj.org/article/7c5a3a971c7f40ea88934267608977f3
Autor:
Hans J. van der Vliet, Arnon P. Kater, Tanja D. de Gruijl, Paul W.H.I. Parren, Rob C. Roovers, Steven T. Pals, Mark-David Levin, Rieneke van de Ven, Anita G. Stam, Renate de Boer, Jana Vree, George L. Scheffer, Roeland Lameris, Iris de Weerdt
Supplementary Tables 1-2 and Figure legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2362ee89f340190459bda2b8bdedcf43
https://doi.org/10.1158/2326-6066.22543959.v1
https://doi.org/10.1158/2326-6066.22543959.v1
Autor:
Hans J. van der Vliet, Arnon P. Kater, Tanja D. de Gruijl, Paul W.H.I. Parren, Rob C. Roovers, Steven T. Pals, Mark-David Levin, Rieneke van de Ven, Anita G. Stam, Renate de Boer, Jana Vree, George L. Scheffer, Roeland Lameris, Iris de Weerdt
Novel T cell–based therapies for the treatment of B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and multiple myeloma (MM), are thought to have strong potential. Progress, however, has been hampered by low efficacy and high toxicit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4993802098a95dc76dd88087515bd4dc
https://doi.org/10.1158/2326-6066.c.6550482
https://doi.org/10.1158/2326-6066.c.6550482
Autor:
Hans J. van der Vliet, Arnon P. Kater, Tanja D. de Gruijl, Paul W.H.I. Parren, Rob C. Roovers, Steven T. Pals, Mark-David Levin, Rieneke van de Ven, Anita G. Stam, Renate de Boer, Jana Vree, George L. Scheffer, Roeland Lameris, Iris de Weerdt
Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18b8e4bbf401445001ae70519575d61e
https://doi.org/10.1158/2326-6066.22543962.v1
https://doi.org/10.1158/2326-6066.22543962.v1